Review
doi: 10.1007/978-0-387-72009-8_2.
Ectodomain shedding of receptor activator of NF-kappaB ligand
Affiliations
- PMID: 17966383
- DOI: 10.1007/978-0-387-72009-8_2
Item in Clipboard
Review
Ectodomain shedding of receptor activator of NF-kappaB ligand
Adv Exp Med Biol.
2007.
Abstract
Receptor activator of NF-kappab ligand (RANKL), a key regulator of osteoclastogenesis, is proteolytically processed and converted to a soluble form. RANKL sheddase and the biologic and pathologic role of RANKL shedding have been undetermined, but the identity of sheddase and its effect on osteoclastogenesis are gradually clarified. The regulatory mechanism and its relevance to some pathologic conditions are to be elucidated.
Similar articles
-
Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.J Immunol. 2007 Jan 1;178(1):192-200. doi: 10.4049/jimmunol.178.1.192. J Immunol. 2007. PMID: 17182555
-
Receptor activator of NF-kappaB (RANK) ligand induces ectodomain shedding of RANK in murine RAW264.7 macrophages.J Immunol. 2010 Mar 1;184(5):2442-8. doi: 10.4049/jimmunol.0901188. Epub 2010 Jan 29. J Immunol. 2010. PMID: 20118276
-
Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242. J Bone Miner Res. 2011. PMID: 20814972
-
Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).Mol Med Rep. 2015 May;11(5):3212-8. doi: 10.3892/mmr.2015.3152. Epub 2015 Jan 7. Mol Med Rep. 2015. PMID: 25572286 Review.
-
RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.Adv Exp Med Biol. 2009;649:100-13. doi: 10.1007/978-1-4419-0298-6_7. Adv Exp Med Biol. 2009. PMID: 19731623 Review.
Cited by
-
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.BMC Cancer. 2015 Nov 25;15:935. doi: 10.1186/s12885-015-1837-1. BMC Cancer. 2015. PMID: 26608463 Free PMC article.
-
Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation.Biomaterials. 2015 Apr;46:58-69. doi: 10.1016/j.biomaterials.2014.12.033. Epub 2015 Jan 17. Biomaterials. 2015. PMID: 25678116 Free PMC article.
-
RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease.Clin Dev Immunol. 2013;2013:412768. doi: 10.1155/2013/412768. Epub 2013 May 15. Clin Dev Immunol. 2013. PMID: 23762088 Free PMC article. Review.
-
HIV-1-Infected Human Macrophages, by Secreting RANK-L, Contribute to Enhanced Osteoclast Recruitment.Int J Mol Sci. 2020 Apr 30;21(9):3154. doi: 10.3390/ijms21093154. Int J Mol Sci. 2020. PMID: 32365752 Free PMC article.
-
Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.Am J Pathol. 2013 Sep;183(3):938-50. doi: 10.1016/j.ajpath.2013.05.024. Epub 2013 Jul 16. Am J Pathol. 2013. PMID: 23867796 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
